Solvonis Therapeutics wants to take esketamine, the molecule in Johnson & Johnson’s Spravato, into moderate-to-severe alcohol use disorder by a short route. SVN-002 is an oral film placed under the tongue and against the cheek, to be given in three supervised clinic sessions, with digital support at home. The company’s argument is that much of the expensive work is already done. The molecule is approved, FDA has agreed that an application can lean on Spravato’s record, and the clinics, controlled-drug procedures and billing Spravato built are already in place.
If each of those holds, SVN-002 would need much less new work than a new drug: a toxicology package, an investigational new drug application, a Phase 2b trial and a pivotal program, with no delivery system to build from scratch. That is the program’s appeal.
What changed this year is how much of that case the company is now presenting as settled. In June, Solvonis reported preclinical bridging data and said it would go back to FDA on toxicology. In its October corporate presentation, the FDA position is headed “FDA CONFIRMED” and the IND is planned for 2027. And at mid-year the company had £659,000 in cash. Together, they describe a regulatory bridge still to be completed and paid for, not a product ready to borrow Spravato’s commercial rails.
What FDA has been shown to agree to
Nothing FDA itself has published. The FDA position rests on a December 16, 2024 pre-IND meeting held by Awakn Life Sciences, which Solvonis acquired in May 2025, and no minutes have been released. Every statement of what FDA said is the company’s account, and that account has been written three ways.
In January 2025, Solvonis said FDA “confirmed that no additional clinical data are required prior to initiating a Phase 2b trial,” and agreed the product could be reviewed under 505(b)(2), the pathway that lets an application rely in part on FDA’s findings for an approved drug, “provided a scientific bridge is established” to it. The chief executive said the product could proceed to Phase 2b “once a suitable scientific bridge to the product has been established.”
In June 2026, describing the same meeting, the company said FDA had “identified systemic exposure to esketamine and relevant metabolite exposure as key considerations” for the IND, and that it “will seek further FDA feedback on the scope and scale of the remaining nonclinical toxicology work.”
In October 2026, the presentation’s slide reads “FDA agreed the 505(b)(2) route, and no additional clinical data are needed before Phase 2b,” describes the route as “based on a scientific bridge to SPRAVATO®,” and sits under a banner reading “FDA CONFIRMED.” The same slide notes that FDA feedback “is not an approval or a guarantee of any outcome.”
The claim about clinical data has been constant since January 2025. What has moved is the condition. “Provided a scientific bridge is established” became “based on a scientific bridge,” which reads as though the bridge were in place.
The bridge so far is one preclinical study. The company reports that, at the same nominal dose, exposure to esketamine and two metabolites, noresketamine and hydroxynoresketamine, after under-the-tongue and cheek dosing fell “within the range” of a nasal esketamine comparator. It has not disclosed the species, the doses, peak concentration, total exposure, time to peak, variability or the criteria a bridge would have to meet. In people, the only data are from a Phase 1 study of 20 healthy volunteers, run by the film’s developer, in which a 50 mg film produced a mean peak plasma level of 96 ng/mL. The presentation sets that beside 101 ng/mL for Spravato’s 84 mg dose, but the Spravato figure is a model estimate from a different study, and a similar peak does not establish similar total exposure.
“No additional clinical data” is not the same as no additional data. The next public signal is FDA’s response on toxicology, then an IND that goes into effect, which would mean FDA has not put the planned trial on hold. Neither would settle the bridge. Whether FDA accepts it as the basis for relying on Spravato’s findings is decided when an application is reviewed, and the company has not said whether it plans a human comparison of exposure against Spravato before then.
The near-term constraint is money
Solvonis reported £659,000 in cash at June 30, 2026, against £1.7 million a year earlier. In August it raised £1.3 million gross in a placing of about 1.08 billion new shares at 0.12 pence. Its annual accounts, approved in April, said its ability to continue as a going concern depended on further equity fundraising, a material uncertainty its auditors also flagged. After the placing, the directors said the group had enough working capital for its operations over the next 12 months.
The company has not said what the toxicology package, the IND or the Phase 2b would cost, or how it would pay for them, and its presentation ties every timeline to “the availability of capital.” A 505(b)(2) route reduces what a sponsor has to generate, not the need to finance what remains. The next milestones that would change SVN-002’s value, an IND that goes into effect and then a Phase 2b result, both lie beyond funding the company has not described.
What has to be true
Four conditions decide whether SVN-002 can reach a Phase 2b result. Two more, delivery and protection, decide what success would be worth, and are taken up below.
The bridge. Shown: one preclinical exposure comparison, described without values. Unresolved: FDA’s view of it and the toxicology scope. What would change the view: the outcome of the further FDA consultation, disclosed exposure values and, eventually, human comparative data.
Money to reach Phase 2b. Shown: enough working capital for 12 months of current operations, by the directors’ assessment. Unresolved: the cost of the next stage and who pays for it. What would change the view: a financing or partnership sized to the program.
Efficacy in alcohol use disorder. Shown: an IV ketamine trial, not this product. KARE, the 96-patient Phase 2 trial behind Solvonis’s UK program, gave three infusions, with therapy or alcohol education, to people with severe AUD who had recently detoxified, and met one of its two co-primary endpoints, days abstinent, but not confirmed relapse. For the film itself, a 28-person placebo-controlled study in people with alcohol problems reported greater engagement with mindfulness practice and transient falls in craving. Unresolved: whether three film sessions with digital support reduce drinking in a broader moderate-to-severe population, against which endpoint. What would change the view: a published Phase 2b protocol, then its result.
Safety in this population. Spravato carries a boxed warning for sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts. Its label says people with a history of drug abuse or dependence “may be at greater risk for abuse and misuse,” that alcohol and other CNS depressants “may increase sedation,” and that blood pressure should be checked before dosing and monitored for at least two hours after. The abuse and CNS-depressant warnings bear directly on a product for people with alcohol use disorder. Solvonis has not said how it would select patients, handle a patient who arrives having been drinking, or monitor sessions. Unresolved: whether the monitoring burden in this population fits a three-visit model in addiction clinics. What would change the view: the Phase 2b protocol’s safety procedures, and FDA’s eventual decision on a REMS.
What does not transfer from Spravato
Spravato’s commercial system works. Johnson & Johnson reported $624 million in worldwide Spravato sales in the third quarter of 2026, up 36.1%, from a product delivered only in certified settings. None of the rails that support those sales belongs to SVN-002.
The REMS is attached to Spravato. Its requirements, from an on-site prescriber and pulse oximeter to patient enrollment and outpatient monitoring forms, cover that product, and whether SVN-002 would need its own is for FDA to decide. Medicare’s two esketamine visit codes, G2082 and G2083, describe esketamine “nasal self-administration” with two hours of observation, and the drug code J0013 is defined as esketamine nasal spray. An oral film falls outside all three as written. Aligning with the structure of supervised-visit coding, as the presentation proposes, is plausible. Inheriting the codes or their payment rates is not something an announcement can establish.
Nor do existing addiction services automatically become SVN-002 sites. SAMHSA’s 2024 survey of 15,953 substance use treatment facilities found 83.8% offering outpatient care and 49.9% offering medication for alcohol use disorder, but only 15.7% listed the DEA among their licensing or certifying bodies. That is a facility-level answer to a survey question. It does not capture every prescriber’s own DEA registration, and it does not measure whether a site could store esketamine, staff two-hour observation or meet a REMS. Solvonis has not said which providers it intends to use. Opioid treatment programs handle controlled drugs under supervision; Spravato-certified clinics have esketamine experience, but whether they would take on alcohol use disorder is not established. Closing the gap between existing and ready infrastructure would cost someone money: Solvonis, a partner or the clinics.
Four times what, exactly
The presentation describes “a U.S. population about 4× that of treatment-resistant depression.” Both numbers are sourced, and they measure different things.
The first, 11.3 million, is the presentation’s figure for people aged 12 and older with moderate-to-severe alcohol use disorder in 2024. SAMHSA’s survey put the total with the disorder at 27.9 million, of whom 40.6% met moderate or severe criteria, which produces that number. SAMHSA’s 2025 survey, released in July, put the total lower, at 25.7 million. The second number, 2.8 million, comes from a 2021 Janssen-funded study that estimated how many adults already receiving medication for depression met a definition of treatment resistance.
The comparison sets a prevalence count against a treated population. In 2024, 2.5% of people with alcohol use disorder received any medication for it, from a short list of approved drugs: naltrexone, acamprosate and disulfiram. A large untreated population is a reason to want a new therapy, not evidence of a large market for this one. Reachable demand depends on how many people seek treatment, qualify for supervised esketamine, can attend sessions and have them paid for. None of those figures is public, and prevalence cannot supply them.
The company’s own figure has moved. In June it estimated “approximately 15 million U.S. adults” in its target population, “approximately five times larger” than the depression comparator. In October it was 11.3 million and about four times.
What would protect it
If SVN-002 works, the public record shows formulation patents, not a proprietary molecule, and they are licensed in. The presentation cites a U.S. patent, 11,992,561, and a European patent, 3,995,137, “covering the esketamine OTF formulation” with an expected term to about 2041, and says “patent grant, scope and Orange Book eligibility are not assured.” Both are owned by LTS Lohmann Therapie-Systeme, the German company that developed the film and ran its Phase 1 study. LTS announced in December 2023 that Awakn had exclusive global rights to the formulation’s use in addiction, anxiety disorders and eating disorders, with milestone payments, royalties and commercial manufacturing at LTS. The amounts have not been disclosed.
The granted U.S. claim covers a film containing 45% to 70% ketamine by weight in a specific blend of polyvinyl alcohol polymers. It does not name esketamine specifically, and it does not claim a method of treating alcohol use disorder. Applications covering the film combined with psychotherapy in alcohol and other substance use disorders have been filed internationally; no grant has been reported. Regulatory exclusivity for a new formulation and indication would depend on FDA’s view of the supporting trials, and the company has not claimed a specific period. The public materials reviewed do not establish how strong the protection would be, and some of the economics of success would flow to the licensor.
Where SVN-002 stands
The constructive case is coherent. Esketamine is an approved, familiar molecule. A 505(b)(2) route, if FDA accepts the bridge, would avoid repeating much of the drug’s basic safety work. A three-session course is short by the standards of psychiatric treatment. Alcohol use disorder is common and undertreated, and a supervised-dosing model already exists that clinicians and payers understand.
Each of those advantages is conditional, and most of the conditions have not yet been met in public.
That makes SVN-002, for now, a program whose value turns on two questions: whether FDA accepts the bridge and toxicology package, and whether Solvonis can fund the work to an IND and a Phase 2b. Peak sales, pricing and a probability of approval cannot usefully be estimated until those are answered and a protocol states the population, dose, sessions, endpoint and monitoring. What would change the view is concrete: FDA’s response on toxicology, an IND in effect, disclosed bridging values, human comparative exposure data, a published protocol, financing or a partner sized to the trial, and FDA’s decision on a REMS.